Related Experiment Videos
Acute treatment for ischemic stroke in 2004
Yousef M Mohammad1, Afshin A Divani, Jawad F Kirmani
1Department of Neurology, Ohio State University, Columbus, Ohio, USA.
Emergency Radiology
|August 17, 2004
Summary
Recent advances in acute ischemic stroke treatment include FDA-approved intravenous thrombolytics and intra-arterial therapies showing benefit within 6 hours. Future treatments like mechanical thrombectomy and neuroprotection are under investigation.
Area of Science:
- Neurology
- Cardiovascular Research
- Emergency Medicine
Background:
- The last decade has seen significant progress in managing acute ischemic stroke.
- Established treatments include intravenous thrombolysis and defibrinogenating agents within 3 hours of symptom onset.
- Intra-arterial thrombolysis trials show benefits for patients treated up to 6 hours post-symptom onset.
Purpose of the Study:
- To review recent advancements in acute ischemic stroke treatment.
- To highlight approved and investigational therapeutic strategies.
- To discuss the promising future of stroke intervention development.
Main Methods:
- Review of Food and Drug Administration (FDA) approved treatments.
- Analysis of clinical trial outcomes for intra-arterial thrombolysis.
- Identification of emerging investigational therapies for ischemic stroke.
Main Results:
- Intravenous tissue plasminogen activator and defibrinogenating agents are FDA-approved for acute ischemic stroke within 3 hours.
- Intra-arterial thrombolysis demonstrates clinical benefit in patients treated within 6 hours.
- Several novel treatments are currently under investigation.
Conclusions:
- The therapeutic landscape for acute ischemic stroke has dramatically improved.
- Expanded time windows for thrombolysis are being explored.
- Future treatments hold promise for enhanced patient outcomes in stroke care.